News|Articles|May 7, 2024
Mobile Visits in Decentralized Clinical Trials: The Past, Present and Future
Author(s)PCM Trials
In March 2024, the US FDA issued its guidance, “Artificial Intelligence & Medical Products: How CBER, CDER, CDRH, and OCP are Working Together,” outlining the agency’s objectives for protecting public health as artificial intelligence (AI) and other technologies become more prevalent in healthcare.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Content
Trending on Applied Clinical Trials Online
1
Former FDA Commissioners Warn New Vaccine Policies Could Undermine Longstanding Regulatory Framework
2
Voyxact Lands FDA Accelerated Approval Following Positive Results in Phase III VISIONARY Trial
3
How the FDA’s CNPV Program Is Reshaping Trial Operations and Accelerated Review Strategies
4
Drug Repurposing Through AI-Driven In-Silico Clinical Trials
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
